Successful administration of a 1-day imported fire ant rush immunotherapy protocol

Judd, Courtney A.; Parker, Amy L.; Meier, Eric A.; Tankersley, Michael S.

doi:10.1016/s1081-1206(10)60497-8

Cited by 22 publications

(6 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Protocols have been developed, which incorporate omalizumab to attenuate adverse effects (114). Recently, a successful 1‐day immunotherapy protocol for fire ant was reported in three cases less than 3 years of age (115). Secondary prevention measures include avoiding bright clothing and perfume and sites where wasps are likely to congregate such as picnic grounds.…”

Section: Management Of Anaphylaxismentioning

confidence: 99%

Anaphylaxis: past, present and future

Ben‐Shoshan

Clarke

2010

Allergy

157

142

View full text Add to dashboard Cite

To cite this article: Ben‐Shoshan M, Clarke AE. Anaphylaxis: past, present and future. Allergy 2011; 66: 1–14. Abstract Anaphylaxis is a clinical emergency, and recent reports suggest increased prevalence. A diverse set of primary genetic and environmental influences may confer susceptibility to anaphylactic reactions. Anaphylaxis presents diagnostic and therapeutic challenges. It often manifests with a broad array of symptoms and signs that might be similar to other diseases. The management of anaphylaxis consists of emergency treatment of acute episodes as well as preventive strategies to avoid recurrences. Treatment is complicated by its rapid onset and progression, presence of concurrent diseases or medications, and need for long‐term allergen avoidance. Health care professionals must be able to recognize the signs of anaphylaxis, treat an episode promptly and appropriately, and provide preventive recommendations. Recognizing the gaps in our understanding and management of anaphylaxis may help identify promising targets for future treatment and prevention and areas that require further study.

show abstract

Section: Management Of Anaphylaxismentioning

confidence: 99%

Anaphylaxis: past, present and future

Ben‐Shoshan

Clarke

2010

Allergy

157

142

View full text Add to dashboard Cite

show abstract

“…4 Conventional immunotherapy schedules can require up to 6 months to reach maintenance, leaving patients with a history of IFA-induced anaphylaxis at risk of fatal reactions during the prolonged buildup period. 9 Several studies have demonstrated the safety and efficacy of 1-and 2-day rush IFA-WBE immunotherapy protocols with and without pre-medications; however, none of the patients studied had a mast cell activation disorder. 8e10 One study has demonstrated that omalizumab decreases the risk of anaphylaxis induced by rush immunotherapy in patients with ragweed allergic rhinitis 5-fold compared with rush immunotherapy alone.…”

Section: Discussionmentioning

confidence: 96%

Ketotifen use in a patient with fire ant hypersensitivity and mast cell activation syndrome

Asawa

Simpson

Bonds

2015

Annals of Allergy, Asthma & Immunology

View full text Add to dashboard Cite

“…14 A case report of 3 children who underwent a 1-day fire ant RIT procedure with a Solenopsis invicta and Solenopsis richteri mix from Hollister-Stier laboratories showed that no systemic reactions occurred. 15 However, a different species of ants were used for the RIT procedure in the current study where Solenopsis invicta ants from ALK were used. In addition, we used a dosage of 0.5 ml of a 1:100 wt/vol ant extract as a target dose for the RIT procedure which was higher than what was used in other RIT protocols.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, we used a dosage of 0.5 ml of a 1:100 wt/vol ant extract as a target dose for the RIT procedure which was higher than what was used in other RIT protocols. 10,14,15 As a result, the difference in the rates of the systemic reactions may be explained by the different sources of allergen extracts and the differences in the rush protocols.…”

Section: Discussionmentioning

confidence: 99%